QLAIRA tablets medication leaflet

G03AB08 estradiol valerate + dienogest • Genito urinary system and sex hormones | Hormonal contraceptives for systemic use | Progestogens and estrogens, sequential preparations

Estradiol valerate and dienogest are used together in combined hormonal treatments, primarily for hormone replacement therapy (HRT) in postmenopausal women and for the treatment of endometriosis. This combination helps balance hormone levels and alleviate symptoms associated with estrogen deficiency.

In hormone replacement therapy, estradiol valerate replaces natural estrogen, reducing menopausal symptoms such as hot flashes, night sweats, and vaginal dryness. Dienogest, a progestin, protects the uterine lining from excessive estrogen effects, preventing endometrial hyperplasia.

This combination is also effective in treating endometriosis, reducing pelvic pain and other associated symptoms. Dienogest inhibits the growth of endometrial tissue, while estradiol helps maintain hormonal balance.

Side effects may include headaches, nausea, breast tenderness, or mood changes. In rare cases, more serious reactions such as blood clots or high blood pressure may occur, making regular medical monitoring essential.

Patients should strictly follow their doctor’s instructions, and long-term use should be periodically evaluated to minimize risks and maximize treatment benefits.

General data about QLAIRA

Substance: estradiol valerate + dienogest

Date of last drug list: 01-06-2025

Commercial code: W63889001

Pharmaceutical form: tablets

Quantity: 1

Product type: original

Price: 63.68 RON

Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.

Marketing authorisation

Manufacturer: BAYER WEIMAR GMBH UND CO. KG - GERMANIA

Holder: BAYER AG - GERMANIA

Number: 6582/2014/01

Shelf life: 5 years

Pharmaceutical forms available for estradiol valerate + dienogest